- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03742401
Treatment of Breast Fibroadenoma With High Intensity Focused Ultrasound (HIFU)
Treatment of Breast Fibroadenoma With High Intensity Focused Ultrasound (HIFU) vs Surgery: A Prospective Randomized Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Fibroadenomas are well-circumscribed benign tumors, easily distinguishable from adjacent normal breast tissue on ultrasound images.
The goal of this protocol is to compare HIFU and surgery in terms of cost, safety, and clinical effectiveness for the treatment of nonmalignant breast tumors.
Fibroadenomas appear to be an ideal target for evaluation of ultrasound guided HIFU treatment. However, not all the FA are suitable for surgical treatment and in many cases surveillance associated or not with hormonal medication may be sufficient for limiting the symptoms at the degree compatible with a good quality of life for the patients. In addition, from the fraction of the patients for which ablation is a genuine medical need due to the severity of the pathology (size, symptoms, disturbed daily activity with possible psychological impact), only a part of them are suitable for undergoing the HIFU treatment.
Therefore, all the patients to be included in this study have an initial indication of surgical resection of the adenoma. Unlike the patients presenting FA and suitable for medication and surveillance, the cases for which surgery is an indication are symptomatic (significant pain, discomfort, anxiety) and/or are presenting a growth observed during their surveillance with ultrasound examination. In addition, all the eligible patients will have to comply with the technical limitations of the HIFU method in terms of lump size, subcutaneous depth, presence of calcifications and other contraindications like presence of breast implants or under areolar location. Knowing that after the age of 45 years the lumps are in many institutions reserved exclusively for surgery in order to eliminate all suspicion of malignancy, the upper age limit is fixed at 45. Further limitations as established by the American Society of Breast Surgeons for potential candidates of percutaneous excision will be added as inclusion criteria for all patients (the lesion must be sonographically visible, the diagnosis of FA must be confirmed histologically, lesions should be less than 4cm in largest diameter).
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Marseille, France, 13003
- Hôpital Européen
-
Montpellier, France, 34925
- CHU de Montpellier
-
Nancy, France, 54000
- Polyclinique Majorelle
-
Nantes, France, 44819
- Polyclinique de L'Atlantique
-
Neuilly-sur-Seine, France, 92200
- American Hospital of Paris
-
Paris, France, 75970
- Hopital Tenon
-
Paris, France, 75010
- Hopital Saint Louis
-
Paris, France, 75651
- Hôpital Pitié-Salpetriere
-
Paris, France, 75012
- Groupe Hospitaliler Diaconesses
-
Rennes, France, 35043
- Clinique Mutualiste la Sagesse
-
Strasbourg, France, 67091
- CHU Strasbourg
-
Valenciennes, France, 59300
- Centre Hospitalier
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Female patients 18 to 45 years old with at least one diagnosed breast fibroadenoma
Diagnosis of fibroadenoma must be based on:
- clinical examination
- ultrasound image alone for patients Under 35 years old. For women older than 35 years, a mammogram will be performed in addition to ultrasound. the BI-RADS score of this mammogram must be less than 3. In all cases where an uncertainly exists, the patient will not be included.
- histological confirmation after core needle biopsy by two independant readers (biopsy must be performed at least two weeks before therapy unless a micro biopsy has been already done less than 3 months before inclusion visit and histopathology slices are available)
the requirements for the distance from the skin and the following régions of the fibroadenoma are:
- depth anterior edge < 19.4mm
- nodule thickness > 7.3 mm
- depth of posterior edge > 12.5 mm
- depth to rib cage > 10mm
- patient's fibroadenoma size is greater to equal to 0.3 cc (measured by ultrasound on the day of the procedure)
- Lesions should be less than 20 mL
- The lesion must be sonographically visible
- Lesions presented during previous surveillance a minimum 20% increase volume AND/OR
- Patient are presenting a pain level >= 3 as meaured on the VAS during the last 30 days AND/OR
- Patient are presenting a anxiety level >= 3 as meaured on the VAS during the last 30 days before selection visit
- Fibroadenoma is palpable
- Patient candidate for sugery
- Patient has signed a written informed consent
- Patient with a social security coverage
Exclusion Criteria:
- Patient is pregnant or lactating
- Patient with history of laser or radiotherapy in the targeted breast
- Core biopsy diagnosis suggestive of cytosarcoma phyllodes tumor or other malignancy
- Patient with breast implant in the targeted breast
- Patient with predominantly liquid nodule
- Macro-calcifications in pre-focal HIFU path
- Nipple and or areola in pre-focal HIFU path
- Patient's fibroadenoma not clearly visible on the ultrasound images (in B-mode) at the inclusion visit
- Scars or moles before the focal point of the HIFU
- Patient participating in another clinical trial involving an investigational drug, or device
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Surgery
|
Traditional open excisional surgery
|
Active Comparator: HIFU (Echopulse)
|
High intensity focused ultrasound (HIFU) non invasive intervention
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of the treatment of breast fibroadenoma by HIFU compared to surgery assessing the total induced cost in both study arms
Time Frame: From day of treatment (Day0) to 18 months after treatment
|
Difference in cost between the HIFU procedure and conventional surgery
|
From day of treatment (Day0) to 18 months after treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of the clinical effectiveness in both arms : Pain level assessment
Time Frame: From 1 day after treatment (Day1) to 18 months after treatment
|
Visual analog scale
|
From 1 day after treatment (Day1) to 18 months after treatment
|
Evaluation of the clinical effectiveness in both arms: Anxiety level assessment
Time Frame: From 1 day after treatment (Day1) to 18 months after treatment
|
Visual analog scale
|
From 1 day after treatment (Day1) to 18 months after treatment
|
Evaluation of the clinical effectiveness in both arms: Volume assessment
Time Frame: From 1 day after treatment (Day1) to 18 months after treatment
|
Ultrasound measurement
|
From 1 day after treatment (Day1) to 18 months after treatment
|
Number of cases needing corrective surgery in case of lack of effectiveness of the primary HIFU treatment.
Time Frame: From 1 day after treatment (Day1) to 18 months after treatment
|
Rate of corrective surgical procedure after non effective HIFU procedure up to 18 months
|
From 1 day after treatment (Day1) to 18 months after treatment
|
Safety of the procedures in both arms: Number of and severity of adverse events in both arms
Time Frame: From day of treatment (Day0) to 18 months after treatment
|
Number of and severity of adverse events in both arms
|
From day of treatment (Day0) to 18 months after treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Richard Villet, PI, Groupe Hospitaliler Diaconesses
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HIFU-Surg-FA
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Fibroadenoma
-
Second Affiliated Hospital, School of Medicine,...OmixScience Co., Ltd.RecruitingBreast Cancer | Breast Fibroadenoma | Breast HypoplasiaChina
-
University of ChicagoGuerbetCompletedBreast Cancer | Breast Neoplasms | Breast Diseases | Breast FibroadenomaUnited States
-
TheraclionActive, not recruitingBreast FibroadenomaBulgaria
-
TheraclionCompleted
-
Medipol UniversityCompletedBreast Cancer | Breast Neoplasms | Breast Diseases | Breast FibroadenomaTurkey
-
TheraclionCompleted
-
David R. Brenin, MDTheraclion SAS, Paris, FranceCompletedBreast FibroadenomaUnited States
-
University Women's Hospital TübingenTheraclionCompletedBreast FibroadenomaGermany
-
InSightecTerminatedBreast FibroadenomaUnited States, Japan
-
TheraclionRecruitingBreast FibroadenomaUnited States
Clinical Trials on Surgery
-
University of AarhusCompletedAcute Post Operative Pain | Chronic Postsurgical PainDenmark
-
International Study Group on Minimally Invasive...Fondazione CARIT; LOGIX S.r.l.Unknown
-
Peking Union Medical College HospitalCompletedPancreatic Neuroendocrine TumorsChina
-
Sunnybrook Health Sciences CentreMcMaster University; Unity Health Toronto; University of Toronto; University of... and other collaboratorsCompleted
-
Hospital Central de la Defensa Gómez UllaClinica Universidad de Navarra, Universidad de NavarraEnrolling by invitationRectal Cancer | PROM | Functional Bowel DisorderSpain
-
Shanghai Zhongshan HospitalUnknownCarcinoma, Pancreatic Ductal | Circulating Tumor CellsChina
-
The Second Hospital of Shandong UniversityRecruitingLung Diseases | SurgeryChina
-
Federal University of São PauloUnknownObesity | LymphedemaBrazil
-
The Christie NHS Foundation TrustUniversity of ManchesterRecruitingQuality of Life | Lung NeoplasmsUnited Kingdom
-
Spinal Surgery Clinic, SträngnäsCompletedLow Back Pain | Pelvic Pain